Category Archives: Generic drug

Dear Prime Minister Modi: Stand firm for affordable medicines

Source: South Asia Foreign Policy As Prime Minister Narendra Modi makes his first official visit to the United States, one issue at the top of the trade agenda is the strikingly different approaches of the Indian and U.S. governments toward … Continue reading

Posted in access to medicines, Compulsory Licensing, Generic drug, Intellectual Property, IPR policy, patent, Patent examination system, Right to Health, Sec 3 (d), USTR 301 report, WTO | Leave a comment

MSF urges Prime Minister Modi to resist US political pressure to restrict global access to medicines

Source: MSF Access September 26, 2014, Delhi/New York – As Indian Prime Minister Narendra Modi makes his first official visit to the United States,Médecins Sans Frontières/Doctors Without Borders (MSF) is urging the Indian government to resist U.S. pressure to drop … Continue reading

Posted in access to medicines, Compulsory Licensing, Generic drug, patent, Sec 3 (d), TRIPS flexibilities | Tagged | Leave a comment

Issues of concern around Commerce and Industry Minister’s Statement on IP Policy

Statement of Organisations and Individuals Tuesday, 23 September 2014 We, the undersigned organisations and individuals, understand that ahead of Prime Minister Narendra Modi’s scheduled visit to the United States, the government has decided to review India’s positions on intellectual property … Continue reading

Posted in access to medicines, Compulsory Licensing, Generic drug, IP Rights, IPR Enforcement, IPR policy, patent, patent evergreening, Patent Opposition, Sec 3 (d), Special 301 report, US International Trade Commission, WTO | Leave a comment

Gilead Close to Sending $84,000 Drug to Poor Countries

Source: Bloomberg 8 Sep 2014 Gilead Sciences Inc. (GILD) is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Posted in access to medicines, Generic drug, Hepatitis - C, Sofosbuvir | Leave a comment

Japan’s attempt to get in stricter patent protection into free trade agreement raises concern

Source: Times of India 2 Sep 2014 NEW DELHI: Even as the Prime Minister’s visit to Japan generates much excitement, there is concern among those working for improving access to medicines regarding Japan’s attempt to get in stricter patent protection … Continue reading

Posted in access to medicines, ASEAN, FTAs, Generic drug, Indian Patent Law, Intellectual Property, IP Rights, Regional Comprehensive Economic Partnership, TRIPS plus | Leave a comment

MSF cautions India on IP inclusion in RCEP talks

Source:Livemint August 26,2014 Mumbai: Medecins Sans Frontieres (MSF), or Doctors Without Borders, an international not-for-profit organisation working in the field of access to affordable medicines, has cautioned India on the inclusion of intellectual property (IP) in the ongoing negotiations of the … Continue reading

Posted in FTAs, Generic drug, HIV/Aids, Intellectual Property, IP Rights, Right to Health, WTO | Tagged , , , | Leave a comment

Médecins Sans Frontières Warns About IP Inclusion In Asian FTA

August 27,2014 The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to … Continue reading

Posted in ASEAN, FTAs, Generic drug, IP Rights, patent, Right to Health, TRIPS plus | Tagged , , , , , , | Leave a comment